NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy
Led by neuroscientist Dr Richard Bergeron, the Ottawa Memory Clinic will be a primary location for Canadian participants.
Drug Development
Astellas and Evopoint sign ADC licensing deal
CHMP recommends GSK’s Blenrep approval for multiple myeloma treatment
Viralgen and Trogenix to progress gene therapy for glioblastoma
Construction begins on MSD’s $1bn biologics centre in Delaware, US
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
DAAN Biotherapeutics and GC Cell partner for CAR-T, CAR-NK therapies
Glycomine raises $115m to advance rare disease therapy into Phase IIb
